PHASE IB STUDY OF COPANLISIB, A PAN PI3K INHIBITOR, IN COMBINATION WITH IBRUTINIB, A BTK INHIBITOR, IN RELAPSED OR REFRACTORY PRIMARY CNS LYMPHOMA